Glenmark Pharmaceuticals informs about company updates

28 Nov 2017 Evaluate

Glenmark Pharmaceuticals has informed that the Baddi unit of the company underwent an US FDA audit from November 6, 2017 to November 11, 2017. The USFDA issued seven observations through the form 483. The company is in the midst of providing a comprehensive response to the observations and would be replying to the FDA shortly on the observations. At this point in time, the company has informed that the Baddi unit contributes approximately 10 percent of the revenue of US sales.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma Share Price

2016.90 30.15 (1.52%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×